Abstract
Perspective is missing on available or required budget for new or expanded vaccination program. Using an Immunisation Planning Tool (IPT), we aimed at quantifying the cost-per-capita of vaccines and of life-long immunization of the current National Immunisation Program (NIP) and possible upcoming changes in the program. The IPT models budgetary impact based on published demographic data, official vaccination program, vaccination coverage rate and cost input assumptions including vaccine list prices as conservative overestimation. The base case preliminary results include 7 or 8 vaccines protecting against 13 or 14 infectious diseases as covered by the Wallonia-Brussels Federation and Flanders vaccination programs, respectively (polio, diphtheria, pertussis, tetanus, hepatitis B, Haemophilus influenza type b, meningococcus C, pneumococcal disease in children, human papillomavirus, measles, mumps, rubella, and influenza in nursing-home residents (Flanders only)). Scenario analyses include new available and registered vaccines. The life-long immunization cost-per-capita in full compliance with current NIP in Flanders is €930; €1090 if the rotavirus vaccine is included; and €2010 if vaccines against Men B, Men ACWY, varicella, influenza, pneumococcal and zoster for all adults 65+ are also included. The per-capita spending on vaccines accounts for 10€/capita/year in both Flanders and Wallonia, according to their current NIP. In Flanders, this cost increases to 11€/capita/year if Rotavirus vaccine is included and to 19€/capita/year if all new available vaccines are considered. The combined total regional budgets for vaccines of Flanders and Wallonia represent less than 0.4% of the federal health care budget in 2020. The federal budget for reimbursed vaccines was separately estimated around €32 million. The life-long immunization cost-per-capita is in the range previously reported by other European Countries. The IPT results and scenarios allow the assessment of the current level of investment in vaccines and provide baseline quantitative perspective for immunisation horizon scanning discussions with policy makers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
